Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in request metadata) on March 25, 2010. The filing serves as a Regulation FD disclosure regarding a press release issued on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The material event reported is the announcement that data for the company's product candidate, OGX-427, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. No financial changes or operational shifts are detailed in the text of this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The company highlighted the upcoming presentation of clinical data for OGX-427 at a major industry conference.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in the report and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the content of the attached press release (Exhibit 99.1) for specific clinical data details regarding OGX-427.
- Confirm the exact dates and location of the American Society of Clinical Oncology Annual Meeting presentation.
- Review subsequent filings for any financial impact or strategic decisions resulting from the clinical data presentation.
- Note the discrepancy between the request metadata company name ("ACHIEVE LIFE SCIENCES, INC.") and the registrant name in the filing ("ONCOGENEX PHARMACEUTICALS, INC.").